abstract |
New vaccines for use as immunotherapeutic agents in the treatment of cancer, particularly but not limited to prostate cancer, are described. The invention relates to cell co-culture techniques which leads to a significant enhancement of the phenotype of cell lines, particularly allogeneic cell lines, towards a more in vivo phenotype resulting in a vaccine reflecting a more realist phenotypic representation of an in vivo tumour. Further, the invention relates to whole cell cancer vaccines having an immunogenic component which comprises co-cultured malignant and non-malignant cells. Such vaccines produced by the various co-culture techniques described have additional advantages over single cell suspension vaccines in the mode of presentation to the immune system which leads to enhanced performance in treating the disease. |